The mRNA cap-binding protein eIF4E (eukaryotic translation initiation factor 4E) permits ribosome recruitment to capped mRNAs, and its phosphorylated form has an important role in cell transformation. The oncogenic function of eIF4E is, however, antagonised by the hypophosphorylated forms of the inhibitory eIF4E-binding proteins 1 and 2. eIF4E-binding protein 1 and 2 (4E-BP1 and 2) are two major targets of the protein kinase mTOR, and are essential for the antiproliferative effects of mTOR inhibitors. Herein, we report that pancreas expresses specifically and massively 4E-BP1 (4E-BP2 is nearly undetectable). However, 4E-BP1 expression is extinguished in more than half of the human pancreatic ductal adenocarcinomas (PDAC). 4E-BP1 shutoff is recapitulated in a mouse genetic model of PDAC, which is based on a pancreas-specific mutation of Kras, the more frequently mutated oncogene in human pancreatic tumours. 4E-BP1 downregulation enhances eIF4E phosphorylation and facilitates pancreatic cancer cell proliferation in vitro and tumour development in vivo. Furthermore, 4E-BP1 loss combined with the absence of 4E-BP2 renders eIF4E phosphorylation, protein synthesis and cell proliferation resistant to mTOR inhibition. However, proliferation can be better limited by a recently developed compound that mimics the function of 4E-BP1 and 2 independently of mTOR inhibition.
INTRODUCTION
One emerging cellular process in cancer biology is the deregulation of translation initiation control. In eukaryotic cells, most mRNAs are translated via a cap-dependent process. Capdependent translation is mediated by the cap-binding protein eIF4E (eukaryotic translation initiation factor 4E). Together with the large scaffolding protein eIF4G and the RNA helicase eIF4A, eIF4E forms the eIF4F complex that recruits the ribosome at the mRNA 5 0 cap structure (for review refer to Sonenberg et al. 1 ). eIF4E level is increased in many human tumours, and eIF4E overexpression promotes tumour formation in animal models (reviewed in Blagden and Willis 2 ). The activity of eIF4E depends also on its phosphorylation in a unique site, which is phosphorylated by the MNK1 and MNK2 (MNK1/2) protein kinases. 3 As both kinases use a docking site in eIF4G, 4 eIF4E phosphorylation is expected to be enhanced when the eIF4F complex is assembled. The use of mice carrying a non phosphorylatable mutant of eIF4E 5 or lacking both MNK1 and MNK2 kinases 6 has revealed that the phosphorylation of eIF4E contributes to cell transformation and tumour development.
The translational function of eIF4E is however antagonised by the hypophosphorylated forms of inhibitory proteins termed eIF4E-binding protein 1 and 2 (4E-BP1 and 2, 4E-BP1/2) (for review refer to Martineau et al. 7 ). Hypophosphorylated 4E-BP1/2 compete with eIF4G for a common binding site on eIF4E, thus resulting in the dissociation of the eIF4F complex. 4E-BP1 and 2 are two major substrates of the serine/threonine kinase mTOR. Consequently, treatment with mTOR inhibitors blocks cell proliferation and reduces neoplasia through inhibition of 4E-BP1/2 phosphorylation, sequestration of eIF4E and inhibition of translation. These observations provided a rationale for the use of mTOR inhibitors in cancer treatments. The first generation of mTOR inhibitors (rapalogs) is derived from rapamycin, a natural allosteric inhibitor targeting only the mTORC1 complex. Rapalogs have been approved for the treatment of renal cell carcinomas, mantle cell lymphomas and pancreatic neuroendocrine tumours. 8 They have, however, produced limited therapeutic effects in many other tumours, including pancreatic ductal adenocarcinomas (PDAC). 9 Better therapeutic effects are expected by the use of new inhibitors (such as PP242, Torin-1 and derivatives) that interact directly with the active site of the kinase, and thus target both mTORC1 and mTORC2 complexes. 8 PDAC is one of the most intractable malignancies. Gemcitabine is the currently used chemotherapeutic compound, but it elicits only minor therapeutic responses and the overall 5-year survival rate remains o5%. 10 Thanks to the generation of mouse models based on the main genetic alterations found in human tumours, considerable progress has been made in understanding the process of pancreatic carcinogenesis. PDAC affects the exocrine compartment of the pancreas whose normal function is to synthesise and secrete digestive enzymes. In the acinar cells of the exocrine pancreas, the regulation of eIF4E activity by its inhibitory proteins has been shown to have a critical physiological role in regulating the biosynthesis of digestive enzymes. 11, 12 However, the status and roles of 4E-BP1 and 2 have never been explored in PDAC. In this study, we show that whereas normal 1 pancreas expresses exclusively 4E-BP1, its expression is severely repressed in half of the human pancreatic tumours. 4E-BP1 loss enhances eIF4E phosphorylation, accelerates cell proliferation and tumour development, and strongly reduces the sensitivity of pancreatic cancer cells to the active-site mTOR inhibitors. We show, however, that compounds mimicking 4E-BP1/2 function independently of mTOR inhibition can substitute for mTOR inhibitors in cancer cells lacking both 4E-BP1 and 2.
RESULTS

Loss of 4E-BP1 expression in pancreatic carcinogenesis
Although the pancreas is the organ that expresses the highest levels of 4E-BP1 (refs 13,14 and data not shown), the status of 4E-BP1 protein in the different cell lineages that compose the exocrine pancreas remained unknown. Consistently with a role of 4E-BP1 in the production of digestive enzymes, 11, 12 the analysis of normal human pancreas by immunohistochemistry revealed that 4E-BP1 is massively expressed in enzyme-producing acinar cells, whereas the protein was in contrast barely detectable in normal duct cells (Figure 1a , normal sample). 4E-BP1 expression was then analysed in a series of 20 human samples, including 3 normal cases obtained after autopsy and 17 PDACs obtained after surgical resections. 4E-BP1 staining was evaluated in acinar and duct cells of normal pancreas, as described above, and in cancerous areas of surgical PDAC samples. The data revealed that 4E-BP1 is either not or poorly expressed in more than half (9/17) of the PDAC samples (Supplementary Table 1) . A typical sample with 4E-BP1 loss in cancerous lesions is shown (Figure 1a , PDAC sample).
The formation of pancreatic tumours is characterised by graded stages of preneoplastic lesions. Two of them have been termed ADM (acinar-to-ductal metaplasia) and PanIN-1-3 (pancreatic (d) 4E-BP1 and 2 protein levels in extracts from pancreas and brains of male and female mice were analysed by western blotting using specific antibodies. Actin was visualised as a loading control. a, acini; d,duct; i, islet; black arrowheads, PanIN; white arrowheads, ADM.
intraepithelial neoplasms 1-3). 15 These progressive lesions are correlated with a temporal sequence in genetic alterations. The mutation of Kras appears as a priming event which when combined with the loss of at least one tumour suppressor, such as p16
INK4
, TP53 and Smad4, eventually produces an aggressive PDAC, containing cancer cells with a duct-like phenotype. 15 To gain insight into the dynamic expression of 4E-BP1 in the process of carcinogenesis, we have analysed 4E-BP1 expression in ADM and PanIN lesions that are found in the periphery of human pancreatic tumours. In the acinar compartment, the massive expression of 4E-BP1 appeared downregulated, as attested by the decrease in 4E-BP1 staining observed in ADM lesions (Figure 1a , white arrowhead). In ducts, 4E-BP1 protein appeared transiently overexpressed, peaking in early PanIN-1 and 2 ( Figure 1a , black arrowheads), and returning to basal low levels or becoming undetectable as the pathology further progresses to PanIN-3 and PDAC.
As ADM and PanIN are generally found in the periphery of human samples obtained after surgical resection of advanced PDAC, these lesions cannot be considered as 'true' preneoplastic intermediates. We have therefore looked at 4E-BP1 and 2 expressions in a dynamic model of pancreatic carcinogenesis based on the pancreas-specific mutation of Kras (hereafter named Pdx1Cre-Kras
G12D
). 15 At 10-month old, 30% of the pancreas of these mice are replaced by preneoplastic lesions consisting of ADM, which progressively convert into PanIN (Figure 1b) . The metaplastic intermediates originate from transdifferentiation of acinar cells into duct-like cells, characterised by the loss of acinar markers such as the transcription factor Mist-1. 16 As observed in human pancreas, 4E-BP1 appears massively expressed specifically in acinar cells of mouse pancreas (Figure 1b . 13 A western blot analysis of extracts from normal pancreas and brain also confirmed that 4E-BP2 is very poorly expressed in the mouse pancreas while this protein is found in the central nervous system (Figure 1d ), as previously described. 13, 17 These data reveal that 4E-BP1 is the only member of 4E-BP family expressed in the pancreas, and that its expression is extinguished early in pancreatic carcinogenesis.
4E-BP1 loss enhances eIF4E phosphorylation As the MNK1/2 kinases use a docking site in eIF4G to efficiently phosphorylate eIF4E, 4 we anticipated that 4E-BP1 extinction (combined with the absence of 4E-BP2) and consequent interaction between eIF4E and the eIF4G-MNK1/2 subcomplexes in pancreatic cancer cells would enhance eIF4E phosphorylation. Such hypothesis is of particular interest in pancreatic tumours, as the MNK1/2 kinases are direct substrates of the MAPK that can be activated downstream of Kras, the most frequently mutated oncogene in pancreatic tumours. Furthermore, a recent report showed that eIF4E phosphorylation correlates with poor prognosis and is further enhanced upon treatment with gemcitabine via the expression of a constitutively active splice variant of MNK2. 18 To test this hypothesis, we first searched for pancreatic cancer cell lines that naturally express different levels of 4E-BP1. To limit the impact that the different genetic profiles of established cell lines could have in data interpretation, we opted for MiaPaca-2 and Panc-1 cells. These two cell lines actually exhibit identical genetic profiles in the main oncogenic pathways of pancreatic cancer, including the activating mutation of the Kras oncogene and alterations in the p16
INK4
, TP53 and Smad4 tumour suppressors (Supplementary Table 2 ). Furthermore, both cell lines express similar levels of eIF3b, eIF4A and eIF4GI, and undetectable levels of 4E-BP2 (Figure 2a ). MiaPaca-2 cells, however, express higher levels of 4E-BP1 than Panc-1 cells do and consistently, while both cell lines contain almost comparable amounts of eIF4E, the level of eIF4E phosphorylation is higher in Panc-1 cells (Figure 2a ). To more directly test for the involvement of 4E-BP1 extinction in enhanced eIF4E phosphorylation, we then monitored the level of eIF4E phosphorylation in MiaPaca-2 cells, where 4E-BP1 expression was permanently silenced using specific short hairpin RNA (shRNA). As expected, 4E-BP1 extinction in MiaPaca-2 cells enhances eIF4E phosphorylation (Figure 2b ). Similar results were obtained when cells were transiently transfected with a small interfering RNA (siRNA) that targets a sequence in 4E-BP1 different from the sequence targeted by the shRNA (data not shown). The status of eIF4E phosphorylation was then explored in human samples. In the normal pancreas, eIF4E appears phosphorylated in enzyme-producing acinar cells (an observation consistent with the high rates of protein synthesis in this compartment), but poorly phosphorylated in duct cells (Figure 2c , left panel). In PDAC samples, a much higher level of phosphorylation is detected in duct-like cancer cells (Figure 2c , right panel). These data indicate that in addition to the expected activation of MNK1/2 kinases due to the mutation of Kras, 4E-BP1 extinction (combined with the absence of 4E-BP2) likely participates in the induction of eIF4E phosphorylation in pancreatic tumours.
4E-BP1 extinction and tumour growth in nude mice As 4E-BP1 loss correlated with Ki-67 positivity in the metaplastic intermediates found in Pdx1Cre-Kras G12D mice (Figure 1c) , we hypothesised that 4E-BP1 extinction could facilitate tumour growth. We therefore verified the involvement of 4E-BP1 shutoff in tumour growth by using a similar inducible cell line. MiaPaca-2 cells were chosen because they still express 4E-BP1 (see above). 4E-BP1 was efficiently silenced in vitro upon doxycycline induction of specific miRNAs (Figure 3a) , and tumour growth in nude mice injected with MiaPaca-2 cells was accelerated after doxycycline treatment (Figure 3b ). Accelerated tumour growth correlated with doxycycline-mediated downregulation of 4E-BP1 in vivo, although no significant difference in Ki67 immunostaining could be detected (Supplementary Figure 2) . Furthermore, in vivo treatment with doxycycline did not permit a full extinction of 4E-BP1 (Supplementary Figure 2) . This is consistent with our previous finding that MirNeg MiaPaca-2 cells possess a high rate of proliferation, and that 4E-BP1 downregulation in MirBP1 MiaPaca-2 cells only accelerates further such proliferation by shortening cell cycle progression. 19 These results show that the lack of 4E-BP1, combined with the absence of 4E-BP2, may participate in tumour development by providing a proliferative advantage to pancreatic cancer cells. 4E-BP1/2 level and sensitivity to mTOR inhibitors Hyperphosphorylation of 4E-BP1 and 2, and consequent increase in the rate of protein synthesis are major pathways elicited by activated mTOR to stimulate the proliferation of cancer cells. Consequently, mTOR inhibitors appear as promising therapeutic compounds. 8 Our data suggest, however, that the efficiency of mTOR inhibitors in pancreatic tumours might be compromised due to 4E-BP1 loss and 4E-BP2 absence. To test this hypothesis, we have first analysed the effect of two mTOR inhibitors, the rapalog RAD001 and the recently developed active-site mTOR inhibitors PP242, 20 in the MiaPaca-2 and Panc-1 cell lines that express different levels of 4E-BP1. The overall data first revealed that upon mTOR inhibition, Panc-1 cells poorly expressing 4E-BP1 survived better than MiaPaca-2 cells regardless of the inhibitor tested (RAD001 or PP242) (Figure 4a ). When the compounds were used at doses that produced their maximal effects on survival, a deeper inhibition could be however obtained with the active-site inhibitor PP242 (5 mM), as compared with that of the allosteric inhibitor RAD001 (0.1 mM) (Figure 4a ). To verify whether such higher resistance of Panc-1 cells to mTOR inhibition was correlated with changes in translation rates, we monitored the rate of protein synthesis using the nonradioactive SUnSET method (based on the measure of puromycin incorporation in elongating peptides). 21 Consistent with a more marked inhibition of cell survival, PP242-mediated inhibition of mTOR attenuated protein synthesis more efficiently than RAD001. However, inhibition of mTOR by PP242 Figure 4 . 4E-BP1 expression correlates with resistance to mTOR inhibitors. (a) MiaPaca-2 and Panc-1 cells were subjected to a MTT assay using increasing amounts of PP242 or a high concentration of RAD001 (mean ± s.e.m. of three independent experiments).
(b) MiaPaca-2 and Panc-1 cells were pretreated with 0.5 or 2.5 mM PP242, or with 0.1 mM RAD001 for 1 h or 10 mg/ml cycloheximide for 15 min. Then, cells were labelled with 1 mg/ml puromycin for 10 min (SUnSET). Extracts were processed for western blotting using the indicated antibodies.
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affected protein synthesis less efficiently in Panc-1 cells compared with MiaPaca-2 cells (Figure 4b , puromycin blot). This difference correlated with the status of 4E-BP1 phosphorylation, but not with changes in S6 protein kinase activity, the other major substrate of mTOR involved in the regulation of protein synthesis. The extents of S6 dephosphorylation upon PP242 or RAD001 treatment were similar in both MiaPaca-2 and Panc-1 cells (Figure 4b , upper panels), indicating a minor contribution of S6 phosphorylation in the effects of mTOR inhibitors. These data thus uncovered in pancreatic cancer cells a strong correlation between the resistance to mTOR inhibitors and the lower capability of limiting protein synthesis due to 4E-BP1 loss and 4E-BP2 absence.
To test more directly for the role of 4E-BP1 levels in determining the efficiency of mTOR inhibitors, we tested the effect of PP242 on translation rates in MiaPaca-2 cells where 4E-BP1 expression was either transiently silenced (using 4E-BP1 small interfering RNAs, data not shown) or permanently silenced using specific shRNA ( Figure 5 ). As observed in Panc-1 cells naturally expressing low levels of 4E-BP1, silencing 4E-BP1 in MiaPaca-2 cells prevented PP242-triggered inhibition of protein synthesis (measured by the SUnSET method) independently of the strong inhibitory effect on S6 phosphorylation (Figure 5a ). The absence of PP242-mediated inhibition of protein synthesis due to the lack of 4E-BP1 was further attested by the absence of a shift from high (polysomes, containing translating ribosomes) to low (40S and 80S, containing non-translating ribosomes) fractions in a polysome profile assay performed in 4E-BP1-suppressed cells (Figure 5b) .
As a consequence of the dissociation of eIF4G-MNK1/2 complex from eIF4E, the binding of the hypophosphorylated forms of 4E-BP1/2 to eIF4E (which can be achieved by mTOR inhibition) compromises eIF4E phosphorylation. 5 We then hypothesised that 4E-BP1/2 absence in pancreatic cancer cells would render eIF4E phosphorylation constitutive and resistant to mTOR inhibitors. This was first tested in MiaPaca-2 and Panc-1 cell lines naturally expressing different levels of 4E-BP1 (Figure 5c , compare lanes 1 and 2 with lanes 7 and 8), and then confirmed in MiaPaca-2 cells where 4E-BP1 is permanently silenced by shRNAs (Figure 5c , compare lanes 3 and 4 with lanes 5 and 6). These data indicate that 4E-BP1/2 levels have an impact on the sensitivity of eIF4E phosphorylation to mTOR inhibitors.
These data thus reveal that targeting mTOR in pancreatic cancer cells, where 4E-BP1 expression is extinguished (and probably in other cancer cells lacking 4E-BP1/2), is probably not a good option to inhibit eIF4E phosphorylation and consequent translation initiation.
As mentioned above, the absence of 4E-BP1 and 2 renders eIF4E phosphorylation insensitive to mTOR inhibitors, suggesting that the translational targets of activated eIF4E involved in cell proliferation cannot be downregulated upon mTOR inhibition. We thus anticipated that 4E-BP1 suppression could render MiaPaca-2 cell proliferation resistant to mTOR inhibitors. A proliferation assay confirmed that MiaPaca-2 cells lacking 4E-BP1 are less sensitive to PP242-mediated inhibition of cell proliferation (Figure 6a) . The inhibition of cell proliferation due to eIF4E sequestration by 4E-BP1/2 has been attributed to the general inhibition of protein synthesis necessary for the completion of the G1 cell growth phase, and to a more specific effect on a subset of mRNA possessing complex 5 0 UTRs, which often encode tumourpromoting proteins. Among the mRNAs shown to be selectively stimulated by activated eIF4E (and therefore selectively inhibited by the 4E-BPs), cyclin mRNAs are critical because they encode proteins required for cell cycle progression. 22, 23 Consistently, in addition to the general decrease in protein synthesis observed above, PP242-triggered inhibition of MiaPaca-2 cell proliferation was accompanied by a sustained decrease in cyclin D1 expression. However, upon 4E-BP1 silencing by small interfering RNAs (data not shown) or by shRNAs (Figure 6b ), cyclin D1 expression became less susceptible to the inhibitory effects of PP242. These data suggest that persistent cyclin D1 expression upon 4E-BP1 loss (and 4E-BP2 absence) may participate in the resistance of pancreatic cancer cells to PP242-triggered inhibition of mTOR activity and cell proliferation.
As an alternative strategy to mTOR inhibitors, we thought that newly characterised molecules that mimic 4E-BP1/2 functions (i.e., prevention of eIF4F complex assembly) would be of great interest in cancer cells lacking 4E-BP1/2. We therefore tested the efficacy of 4E2RCat, a compound isolated from a high throughput screening of molecules that inhibit the interaction between eIF4E and eIF4G. 4E2RCat appears as a specific inhibitor of capdependent translation with limited effects on IRES-driven translation. 24 Interestingly, the proliferation of MiaPaca-2 cells was efficiently blocked by 4E2RCat and, more importantly, such inhibition was independent of the intracellular level of 4E-BP1 (Figure 6c ). Figure 5 . 4E-BP1 silencing renders protein synthesis and phosphorylation of eIF4E resistant to mTOR inhibition. (a) Scramble or 4E-BP1 shRNAexpressing MiaPaca-2 cells were treated and subjected to a SUnSET assay, as described in Figure 4B . Cell lysates were subjected to western blotting using the indicated antibodies. (b) Cell lines from (a) were treated with 1 mM PP242 (red) for 1 h or left untreated (blue). Extracts were separated on 10-50% sucrose gradient and subjected to a polysomal analysis. 40S ribosomal subunits, 80S ribosomes and polysomes are indicated. (c) Panc-1 cells and MiaPaca-2 cells from (a) were treated with 2.5 mM PP242 for 1 h or left untreated. Cell lysates were subjected to western blotting using the indicated antibodies.
Taken together, these data demonstrate that a sizable fraction of human pancreatic adenocarcinomas does not or poorly express the critical mTOR targets, 4E-BP1/2. This results in enhanced phosphorylation of eIF4E, faster cell proliferation and tumour progression. They also reveal that increased resistances of eIF4E phosphorylation and cancer cell proliferation to mTOR inhibitors due to the lack of 4E-BP1/2 proteins could be circumvented by the use of molecules mimicking 4E-BPs function independently of PI3K/Akt/mTOR and 4E-BP1/2 status.
DISCUSSION
Although 4E-BP1 and 4E-BP2 are ubiquitously expressed, the amount of each homologue significantly varies among tissues. 13, 14 Our data reveal that 4E-BP1 is massively expressed in the acinar compartment of the exocrine pancreas. However, 4E-BP1 expression in acinar cells dramatically drops early in the process of pancreatic carcinogenesis. Such a strong decrease accompanies the transdifferentiation of acinar cells into metaplastic intermediates that acquire a duct-like phenotype (ADM). This suggests the existence of (one) specific factor(s) responsible for 4E-BP1 expression in differentiated acinar cells, which remain(s) to be identified. Consistently with the loss of 4E-BP1 expression in the process of acinar cell transdifferentiation into duct-like cell, 4E-BP1 protein is barely detectable in normal duct cells. 4E-BP1 levels appear, however, transiently increased in early PanIN lesions. Such a transient induction in duct cells could be explained by our earlier report indicating that 4E-BP1 is a direct target of the transcription factor SMAD4. 19 The role of SMAD4 in PDAC has been linked to its function in TGFb signalling. It is thought that through SMAD4 (also termed DPC4, deleted in pancreatic cancer locus 4), TGFb exerts primarily a protective effect on duct cells. Upon Smad4 deletion, however, TGFb exerts pro-tumoral actions via the targeting of other signalling pathways. We have shown that 4E-BP1 induction is important for TGFb-mediated inhibition of cell proliferation. It is therefore conceivable that TGFb exerts its initial protective effects in part through a 4E-BP1-dependent inhibition of duct cell proliferation. Consistently, we found that the pattern of 4E-BP1 expression matches perfectly to that of SMAD4 in the different human pancreatic lesions (Supplementary Figure 1 and Supplementary Table 1) . As the gene encoding 4E-BP1 protein is neither deleted nor mutated in pancreatic tumours, 25 and as its promoter does not appear hypermethylated in the different human-tumour-derived pancreatic cancer cell lines we have tested (not shown), Smad4 deletion provides a highly probable explanation for 4E-BP1 downregulation in pancreatic tumours. Regardless of the origin of pancreatic cancer cells (acinar or duct cell), neither 4E-BP1 nor 4E-BP2 were expressed in half of the advanced pancreatic tumours. This is of particular interest in pancreatic cancer because, as opposed to many other cancers, the inactivation of 4E-BP1/2 cannot be explained by a direct activation of the PI3K-AKT-mTOR pathway, as only a very few number of patients with pancreatic tumours harbour mutations of PI3K, AKT or PTEN. To our knowledge, PDAC is the first example of cancer with no 4E-BP. In all other tumours, at least one 4E-BP is indeed expressed. The antitumoral activity of 4E-BP1/2 in these tumours is, however, compromised by hyperphosphorylation [26] [27] [28] due to activation of the mTOR pathway. As hyperphosphorylation of 4E-BP1/2 gives a proliferative advantage to cancer cells, and as 4E-BP1/2 are phosphorylated by mTOR, the use of active-site inhibitors of mTOR in cancer therapy appears promising. As shown in this paper, this could however not apply for PDAC tumours lacking both 4E-BP1 and 2 ( Figure 7 ). Consistently with our findings, a recent report indicates that the eIF4E/4E-BP ratio, rather than their individual protein amount or phosphorylation status, should be considered to predict the efficacy of mTOR inhibitors in tumour treatment. 29 One alternative therapeutic strategy in tumours lacking 4E-BP1/ 2 would be the use of compounds that mimic 4E-BP1/2 functions independently of mTOR inhibition. 24, 30 The pertinence of this alternative strategy is supported by the present study showing that 4E2RCat, one of the recently developed 4E-BP mimics, is capable of limiting proliferation of pancreatic cancer cells devoid of 4E-BP. The use of a related 4E-BP mimic (4E1RCat) has also been shown to be well-tolerated in mice and to sensitise tumour growth to various chemotherapies, leading to an increased tumour-free survival. 30 However, higher affinity to eIF4E and bioavailability of 4E-BP mimics are now needed to improve the inhibition of protein synthesis and eIF4E phosphorylation, which remain so far limited (ref. 28 and data not shown). The development of such optimised compounds offers new perspectives in combinatory therapeutics.
MATERIALS AND METHODS Reagents
Antibodies used are as follows: anti-eIF4GI was obtained from Dr N Sonenberg (McGill University, Montreal, Quebec, Canada). 4E2RCat was described elsewhere. 24 Anti-puromycin (12D10) was obtained from Dr P Pierre (Centre d'Immunologie de Marseille-Luminy, Marseille, France). Cell lines from (a) were serum-starved overnight followed by 1-h pretreatment with 2.5 mM PP242 or vehicle alone. Cells were then stimulated with 10% fetal calf serum for 6 h. Cell lysates were subjected to western blotting using the indicated antibodies. (c) Cell lines from (a) were subjected to a MTT assay using 10 mM 4E2RCat (mean ± s.e.m. of three independent experiments).
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Cell culture
Panc-1, MiaPaca-2 pancreatic cancer cell lines and MiaPaca-2 cells expressing doxycycline-inducible miRBP1 or miRNeg were cultured as previously described. 19 Constitutive silencing was obtained using pLKO vectors (Sigma-Aldrich), as previously described. 31 shRNA vector accession numbers are: 4E-BP1 TRCN0000040203 and non-target shRNA control SHC002. Small interfering RNAs targeting 4E-BP1 (Applied Biosystems and Life Technologies, Carlsbad, CA, USA, forward 5 0 -CAAGAACGAACCCUUC CUU-3 0 and reverse) were transfected using the siPort NeoFx reagent (Applied Biosystems and Life Technologies), according to the manufacturer's instructions.
MTT assay
Cells (3 Â 10 3 ) were seeded in 96-well plate in culture media supplemented with 2% SVF. The next day, cells were treated with the indicated concentration of PP242 or 4E2RCat. After 3 days, MTT was added at 0.5 mg/ml for 3 h. Cells were then washed with phosphate-buffered saline and lysed with 100 ml of DMSO. Viability was estimated by measuring absorbance at 590 nm on MRX plate reader (Dynex Technologies, Guernsey, Channel Islands, GB). Results are expressed as a percentage of untreated cells.
SUnSET assay
The SUnSET assay was used to monitor the rate of protein synthesis. Briefly, 10 min prior to harvesting the cells, puromycin was added to culture medium at 1 mg/ml. As a control, cycloheximide was added at 10 mg/ml 15 min before puromycin addition, resulting in complete blockade of protein synthesis. Cell extracts were then processed for western blotting using antipuromycin antibody.
Proliferation assay Cells (3 Â 10 4 ) were plated in six-well dishes in culture media supplemented with 2% fetal calf serum and daily treated with 0.5 mM PP242. Cells were counted daily with a Coulter counter (Beckman Coulter, Danvers, MA, USA). Results are expressed as a percentage of untreated cells.
Polysome profiling
Scramble or 4E-BP1 shRNA-expressing MiaPaca-2 cells were treated for 1 h with 1 mM PP242 prior to harvesting. Polysomes analysis was performed as described. 32 
SDS-PAGE and western blotting
Cells were harvested on ice, washed twice with cold phosphate-buffered saline and lysed in 50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1 mM EDTA, 1% NP-40 supplemented with protease and phosphatase inhibitors. Protein concentration was measured using Protein Assay reagent (Bio-Rad, Hercules, CA, USA), and equal amounts of proteins were subjected to SDS-PAGE and transferred onto nitrocellulose membrane (BioTraceNT; Pall Corp., Pensacola, FL, USA). Membranes were saturated in 5% non-fat dry milk, incubated overnight with primary antibodies in 5% BSA, washed and revealed according to Cell Signaling Technology protocol. doctoral fellowships. Rania Azar, David Mü ller and Charline Lasfargues were recipients of doctoral fellowships from ARC, La Ligue Nationale Contre le Cancer and CFP, respectively. Rodica Anesia was supported by the RITC foundation. We thank Dr Marlène Dufresne, Dr Véronique Gigoux and Mr Pascal Clerc for their help in characterising Pdx1Cre-Kras G12D mice. We thank Professor Nahum Sonenberg for antieIF4GI antibody and Dr Philippe Pierre for the anti-puromycin antibody.
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